InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Effect of pemafibrate on fatty acid levels and liver enzymes in non‐alcoholic fatty liver disease patients with dyslipidemia: A

Body Composition Assessment
Seko et al.
Used Parameters : BFM, SMM

Publication Year : 2020

Country : Japan

Journal : Hepatology Research

Aim Dyslipidemia (DL) is commonly associated with non‐alcoholic fatty liver disease (NAFLD). Pemafibrate, a selective peroxisome proliferator activated receptor α modulator (SPPARMα), has been shown to improve liver function among patients with DL. The aim of this single‐arm prospective study is to evaluate the efficacy of pemafibrate in NAFLD patients with DL. Methods Twenty NAFLD patients with DL who received pemafibrate (0.1 mg) twice a day for 12 weeks were prospectively enrolled in this study. The primary end …
Full text